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A reduced polyoxovanadate functionalized with bisphosphonate 
molecules was synthesized and used to prepare in one step hybrid 
organic-inorganic polyoxometalate decorated gold nanoparticles. 
These new composites were shown to strongly inhibit P. 
aeruginosa and S. epidermidis biofilms growth, the three 
components constituting the nanoparticles (Au
0
 core, vanadium 
and alendronate) acting synergistically. 
Nowadays, the wide use of antibiotics has led to the emergence of 
resistant bacteria causing serious public health problems. Antibiotic 
resistance currently includes all known classes of natural and 
synthetic compounds leading to an urgent requirement for 
alternatives.
1
 Among the different resistances developed by 
bacteria, some bacteria populations use cell attachment to solid 
substrates forming associations named biofilms.
2
 Particularly, 
bacterial biofilms are much more resistant to antibiotics than 
planktonic cells because of the generation of extracellular 
polymeric substances, which impede the penetration of 
antibacterial agents and reduce growth rates of the biofilm 
cells, impacting the effectiveness of antibiotics capable of 
targeting rapidly multiplying cells.
3,4
 Recently, the use of 
antimicrobial nanomaterials has attracted great attention 
because of their ability to disrupt the bacterial membranes and 
to hinder biofilm formation.
5,6
 Several nanomaterials, such as 
silver, copper or zinc oxide nanoparticles (NPs), exhibit intrinsic 
antibacterial activity.
1
 Nevertheless, their toxicity remains 
problematic. In contrast, it has been evidenced that gold 
nanoparticles (AuNPs) are non toxic,
7–9
 and in the last decade 
conjugates of AuNPs with antibiotics
10–14
 or other antibacterial 
agents
15–19
 have been shown to improve antibacterial activity 
against biofilms. Besides, several polyoxometalates (POMs), which 
can be seen as negatively charged molecular oxides incorporating 
metals (mainly tungsten, molybdenum and vanadium) in high 
oxidation states,
20
 have shown important antibacterial 
activity,
21–26
 and notably two examples of antibiofilm POM 
composites have been reported in the literature.
27,28
 In this 
context, the use of POMs as active antibacterial agents 
supported by AuNPs represents a promising alternative. The 
relevance of this approach to the elaboration of antibacterial 
agents is supported by the works of Daima et al., which 
showed that AuNPs post-functionalized by purely inorganic 
commercial POMs exhibit antibacterial activity against the 
non-resistant bacteria E. coli.
29,30 
In addition, precedent works 
have established that POMs containing Mo
V
 or V
IV
 ions can be 
used as reducing agents for the synthesis of a large variety of 
POM functionalized metallic NPs. Importantly, AuNPs 
consisting of a metallic core stabilized by POMs in their 
oxidized form have been obtained in one step, at room 
temperature and in water.
31–33
 This synthetic strategy has 
however only been exploited for purely inorganic reduced 
Scheme 1: Schematic representation of CitNPs, CitNPs@POVred and NPs@POV 
synthesis. 
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POMs, while the use of reduced hybrid organic-inorganic 
polyoxometalates could lead to antibacterial materials 
combining the properties of AuNPs, POMs and biologically 
active organic substrates. The chemistry of POMs structured 
by bisphosphonate ligands (BPs) has been widely studied,
34–40
 
and in particular several molybdenum, tungsten and vanadium 
complexes incorporating the alendronate ligand 
[O3PC(C3H6NH3)OPO3]
4-
 have been obtained.
20,41
 Interestingly, it 
has also been shown that alendronate itself increases 
antibiofilm effects when combined with bioactive glass.
42 
Considering inorganic POMs, it has been evidenced that 
compounds incorporating vanadium centers exhibit the 
highest antibacterial activities.
19 
It follows that the study of the 
antibacterial properties of systems combining alendronate 
molecules, POMs containing vanadium ions and AuNPs 
appears to be particularly attractive. 
Herein, we report on the inhibition of Gram-negative and 
Gram-positive bacteria biofilms growth by such composites. A 
reduced polyoxovanadate (POVred) functionalized by 
alendronate ligands was first synthesized. Then, the ability of 
this reduced POVred to act as both reducing and stabilizing 
agent was exploited
32,43
 to prepare in one step alendronate 
POVred capped gold NPs (NPs@POV). In parallel, citrate-
stabilized gold nanoparticles (CitNPs) functionalized with 
hybrid POVs in their reduced form were prepared for 
comparison of the activities of the two systems (Scheme 1). 
Finally the antibacterial properties of these new NPs@POV 
hybrid materials toward biofilms formation of Pseudomonas 
aeruginosa and Staphylococcus epidermidis, were studied. To 
the best of our knowledge, this work represents the first 
investigations of materials associating NPs, POMs and 
biologically active organic substrates for antibiofilm 
applications. 
 
Results and discussion  
Polyoxovanadate and nanoparticles synthesis and 
characterizations 
First, a reduced polyoxovanadate (V3(Ale)3 also called POVred) 
was synthesized by mixing sodium metavanadate and 
alendronic acid at pH 4.7 in water. In this synthesis, the V
V
 ions 
are likely reduced by triethylamine, which is added in the 
medium to increase the pH (see experimental section, ESI†). 
Despite numerous efforts, only low quality single-crystals were 
obtained. However, data collection at the synchrotron allowed 
solving the structure of the synthesized compound. In the 
structure of POVred, two independent molecules are in the 
asymmetric unit, which only differ by the position of the alkyl chain 
of one of the alendronate ligand (Fig. 1 and S1, ESI†). X-ray 
diffraction studies thus evidence the formation of the title 
complex Na3[V3O3(H2O)(O3PC(C3H6NH3)(OH)PO3)3]·10H2O 
(V3(Ale)3). This POVred is reminiscent of the zoledronate compound 
Na3[V3O3(H2O)(O3PC(C4H6N2)(OH)PO3)3]·12H2O (V3(Zol)3) previously 
characterized by some of us.
44
 In both V3(Zol)3 and V3(Ale)3, three 
V
IV 
ions (Bond Valence Sums for the vanadium ions in V3(Ale)3 = 
3.80-4.05, Fig. S1, ESI†) form an isosceles triangle, the vanadium 
centers being in distorted octahedral environments. Three 
alendronate moieties occupy the edges of the triangle, acting as 
tetradentate ligands by connecting two by two the vanadium ions. 
Each vanadium center is connected to a terminal oxygen atom 
(dV=O=1.63-1.65 Å). Two of these V=O bonds (V2=O and V3=O, Fig. 
1) point to the outside of the molecule while the third tone (V1=O) 
points to the inside. Finally, the coordination sphere of the V1 atom 
is completed by a terminal water molecule while the V2 and V3 
atoms are weakly bound to the O=V1 oxygen atom (dV-O = 2.76 and 
2.73 Å, respectively).Energy-dispersive X-Ray (EDX) spectroscopy 
measurements are in agreement with P:V:Na ratios of 6:3:3 (ESI†). 
This is confirmed by Inductively Coupled Plasma Atomic 
Emission Spectroscopy (ICP-OES), with a determined P/V ratio of 
2.04. Elemental analysis further confirms the proposed formula 
(Experimental section, ESI†). The TGA curve (Fig. S2a, ESI†) 
reveals three steps that can be attributed to water removal, 
ligand decomposition and finally formation of inorganic oxides 
(final experimental weight loss 41.0%, calculated 39.0%). 
Finally, the infrared spectrum of POVred (Fig. S2b, ESI†) presents 
the characteristic bands of both the P-O/P=O groups in the 1039-
1086 cm
-1
 range and P-O and V=O/V-O groups in the 929-999 cm
-1
 
range. 
POVred was then used to prepare in one step functionalized 
polyoxovanadate decorated gold nanoparticles. While reduced 
POVs have already been considered for the one pot 
preparation of metallic nanoparticles,
45,46
 it rapidly appeared 
that the nanoparticles synthesis protocol with the reported 
hybrid POVred needed to be tailored. In order to prevent the 
POVred denaturation, the synthesis was carried out by adding 
an aqueous solution of HAuCl4 basified to pH = 6 to an 
aqueous solution of POVred at pH = 6. Indeed, the IR spectrum 
of the powder obtained by dissolution in water (pH 6) of 
POVred followed by the addition of ethanol is similar to that of 
POVred (Fig. S2b, ESI†), strongly suggesting that the title 
complex is stable in this medium. Additionally, an excess of 
POM was used (ɣ = [HAuCl4]/[POM] = 0.3) to ensure the total 
reduction of the Au
III
 ions (see ESI† for details). The colour 
change of the solution from turquoise to pink was indicative of 
the formation of the NPs@POV (POV being the oxidized form 
of the POVred) gold nanoparticles, as confirmed by the 
presence of a surface resonance plasmon (SPR) band at 531 
nm in the UV-spectra (Fig. 2a). In parallel, the CitNPs 
V1
V3V2
Fig. 1: Ball-and-stick representation of one of the molecule present in the 
structure of the V3(Ale)3 complex. Purple sphere = V, green spheres = P, black spheres 
= C, red spheres = O, blue spheres = N; H atoms were omitted for clarity. 
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synthesized following the Turkevich method
47
 and the POVred 
functionalized citrate nanoparticles (CitNPs@POVred), prepared 
according to the procedure previously described
48
 for the 
grafting of Keggin polyoxotungstates, both show the expected 
narrow band centered at 520 nm characteristic of particle size 
of ca. 15 nm (Fig. 2a). Note that the shift in the position of the 
SPR bands between the NPs@POV and CitNPs@POVred is 
characteristic of the different size of the nanoparticles. 
 
The size and dispersion of NPs@POV, CitNPs@POVred and 
CitNPs were determined from Transmission Electron 
Microscopy (TEM) (Fig. 2b and Fig. S3, ESI†) and Dynamic Light 
Scattering (DLS) analyses (Fig. 2c). TEM images revealed 
particle sizes of 30.8 ± 9.4, 15.1 ± 1.9 nm and 14.8 ± 1.9, for 
NPs@POV, CitNPs@POVred, and CitNPs, respectively. As 
expected, the hydrodynamic diameter measured by DLS is 
larger for the three different batches of particles as it takes 
into account the presence of hydration layers, but also of POM 
layers for the two decorated NPs, not visible on TEM images. 
Besides, the zeta potential of CitNPs@POVred (-49.6 ± 1.7 mV) 
is lower than the zeta potential of the pristine CitNPs (-42.1 ± 
3.9 mV), which can be due to the adsorption at the surface of 
the NPs of the triply negatively charged POV. The zeta 
potential of NPs@POV (-44.1± 2.8 mV) is slightly less negative 
than for CitNPs@POVred. This can be attributed to the 
oxidation of the V
IV
 centers during the formation of the 
NPs@POV. Attenuated Total Reflectance Fourier Transform 
Infrared spectroscopy (ATR-FTIR) has also confirmed the 
presence of POVs at the surface of both NPs@POV and 
CitNPs@POVred, the V-O vibrations related to the POVred 
together with the P-O vibrations and NH3 deformations related 
to the alendronate ligand being observed in the IR spectra (Fig. 
S4 and Table S1, ESI†). ICP-OES allowed confirming the 
presence of V and P in stoichiometric proportion compared to 
the initial POV, with a P/V ratio equal to 2.0 ± 0.1 for 
NPs@POV and 1.9 ± 0.1 for CitNPs@POVred. Moreover, taking 
into account the Au/V ratio determined by ICP and the size of 
the NPs, the number of POV per nm
2 
was estimated to 38±8 
for the spherical 30.8 nm NPs@POV and 23±5 for the 15.1 nm 
CitNPs@POVred (see ESI† for details). We can note that the 
coverages are too high to correspond to a monolayer, which 
would lead to a maximum of 6 POV/nm
2
 (see ESI† for details). 
Therefore, ICP data clearly corroborate the presence of POV 
multilayers as previously discussed on the basis of DLS 
measurements.  
 
Inhibition of Gram-negative and Gram-positive bacteria 
biofilms growth by CitNPs, CitNPs@POVred and NPs@POV 
 
The optical density method (OD620nm) based on crystal violet 
staining was used to investigate the effect of CitNPs, 
CitNPs@POVred and NPs@POV on P. aeruginosa ATCC® 
27853
TM 
and S. Epidermidis CIP 105 777 biofilms formation 
(see ESI† for details).
49
 These Gram-negative and Gram-
positive bacteria, respectively, represent excellent model for 
inhibition biofilm growth studies as they have been shown to 
Fig. 2: Characterization of CitNPs, CitNPs@POVred and NPs@POV. UV-vis spectra and colloidal suspension pictures (insert) (a), TEM images (b) and particle size 
distribution histograms and dynamic light scattering size and zeta potential values (c).  
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severely develop on medical device surfaces, causing serious 
nosocomial infections.
50–53
 The biofilm formation was examined 
over periods of 24 and 48 hours (Fig.3). The antibacterial 
activities of POVred and alendronate at concentrations higher 
to those established for the functionalized NPs were also 
determined as references for the two different strains.  
 To investigate the possible influence of the particle size on the 
antibacterial activity, the inhibitory effects of citrate gold 
particles functionalized with POVred (CitNPS@POVred) with two 
different sizes (15 and 47 nm) have been investigated on P. 
aeruginosa. The synthesis and characterization of the 47 nm 
diameter AuNPs are described in the SI (see experimental 
section and Figure S5). The antibacterial activities of the 15 
and 47 nm NPs have been found to be similar (Figure S6). 
Therefore, we can assume that the size of the nanoparticles 
cannot be regarded as a determining factor influencing the 
antibacterial activity.  
For P. aeruginosa, the bacterial growth was strongly inhibited 
after 24 hours of treatment by both NPS@POV and 
CitNPs@POVred, with a decrease of biofilm formation of ca. 
60% compared to the control experiment. Noticeably, the 
biofilm growth inhibition is not significant for neither the 
unfunctionalized CitNPs nor the POVred complex, when utilized 
separately, this highlights a synergistic effect between the 
AuNPs and the POV. These results suggest that the gold 
nanoparticles could act as carriers to improve the penetration 
of the POV into the bacteria. This trend is confirmed after 48 
hours of treatment, with a decrease of the biofilm formation 
of ca. 80% for NPS@POV and CitNPs@POVred. Noticeably, after 
48h of treatment with alendronate and CitNPs, an antibacterial 
activity is observed as biofilm growth inhibition was around 
60%. However this antibacterial effect remains lower than the 
one observed for POVs decorated nanoparticles, confirming 
the synergistic effect. 
Focusing now on S. epidermidis, Fig 3(b), it was observed that 
only the NPS@POV induce a significant decrease of the biofilm 
formation starting from 24 h of treatment, and, very 
interestingly, this effect is very strong( > 80%). The high 
antibacterial activity of the NPS@POV compared to the 
absence of activity of the CitNPS@POVred against S. epidermidis 
can be tentatively attributed to the oxidation state of the 
vanadium centers (V
IV 
in CitNPs@POVred and V
V
 in NPS@POV). 
Finally, we can also note that the antibiofilm activity of the 
NPS@POV against S. epidermidis remains unchanged after 
additional 24h. 
The effect on the biofilms growth of the NPS@POV 
concentration in the 0.1 – 1 nM range was also studied for 
both strains (Figure S7, ESI†). For a concentration of 0.1 nM, a 
decrease of the P. aeruginosa biofilm formation of 50% after 
24 h of treatment was observed, with no further evolution 
after 24 h. At 0.2 nM, a decrease of 60% after 24h and 80% 
after 48h were determined, indicating that a 0.2 nM 
concentration of NPS@POV is sufficient to obtain a strong 
antibacterial effect against this strain. Regarding S. epidermidis, a 
decrease of the biofilm formation of 40 and 70% upon 24 and 
48h of treatment, respectively, were observed for a 
concentration of 0.6 nM. The maximum of antibacterial effect 
was found for a concentration of 1nM, with ca. 80% of 
inhibition of the biofilm formation after 24h.  
 
In order to observe possible changes of the morphology of 
bacteria, scanning electron microscopy (SEM-FEG) micrographs 
of the P. aeruginosa and S. Epidermidis were recorded after 
24h in presence and in absence of NPS@POV (Figure S8, ESI†). 
We used NPS@POV as an example as these hybrids show a 
good antibacterial activity with both bacterial strains.  
The SEM images of the two bacteria without treatment 
showed intact bacterial membranes with P. aeruginosa rod like 
Fig. 3: The effect of CitNPs (1.3 nM), CitNPs@POVred (1.3 nM),  NPs@POV (1.0 nM) , alendronate (540 μM), and POVred (180 μM) on biofilm formation by (a) P. 
aeruginosa and (b) S. epidermidisafter incubation for 24 and 48h in 96-well plates. The values of the experimental groups were compared with the control group. 
Statistical significance was analyzed by Students’s T-test to detect the presence of statistically significant differences (*** p<0.001, **p<0.01, *p<0.05)***) For 
CitNPs, CitNPs@POVred and NPs@POV the numbers in brackets correspond to the concentration in gold nanoparticles 
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shape (Figure S8a, ESI†) and S. Epidermidis spherical shape 
(Figure S8c, ESI†). In contrast, the cell envelopes of P. 
aeruginosa and S. Epidermidis treated with NPS@POV are 
damaged and appear pierced causing the leakage of the 
cytoplasmic content and the collapse of the bacteria (Figure 
S8b,d, ESI†). From these results, it could be concluded that 
NPS@POV seriously affect the bacterial membrane integrity 
causing bacteria death. The exact antibacterial mechanism is 
however not well elucidated and will be investigated in future 
works.  
Conclusions 
In conclusion, we have used a new reduced polyoxovanadate 
V3(Ale)3 incorporating the biologically relevant alendronate 
ligand to prepare in one-pot, in water, at room temperature 
and in absence of any additional surfactant the hybrid 
functionalized gold nanoparticles NPS@POV. The optimized 
synthetic protocol produced size-controlled monodispersed 
stable NPs. The POVred thus acts as a reducing agent but also as 
capping agent to stabilise the nanoparticles. The 
nanocomposites were thoroughly characterized by TGA, ATR-
FTIR, UV-Vis, DLS, TEM, EDX and elemental analysis 
experiments. The high antibiofilm activity of NPS@POV 
towards both the gram-negative and gram-positive resistant 
bacteria was evidenced. Importantly, comparative studies 
strongly suggest that the three components constituting the 
NPS@POV (Au
0
 core, vanadium and alendronate) act 
synergistically. The activity of POVred functionalized citrate gold 
nanoparticles CitNPs@POVred was also studied, allowing to 
conclude that the oxidation state of the vanadium centers 
constituting the POM may play a significant role on the 
inhibition of gram-positive bacteria biofilm growth. This work, 
which to the best of our knowledge represents the first 
investigation of POM-functionalized NPs for antibiofilm 
applications, opens the way to a new generation of antibiofilm 
agents. We are currently investigating the influence of the 
nature of the polyoxometalate on the biological properties of 
such nanocomposite. Also, an advantage of alendronate is that 
it can be easily functionalized via its amino group. We are thus 
also presently working on the elaboration and the 
investigation of the inhibition of biofilm growth activity of 
antibiotic/alendronate/polyoxometalate NPs systems.  
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